SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
Cancer genetics is the study in humans and other animals of heritable gene variants that cause or confer altered risk of tumour or hematological malignancy. Individual cancer risk varies and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback